Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476337 | 1.00 | CTSK (0.49) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL1655475 | 1.00 | CTSK (0.49) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL23990580 | 0.88 | JAK3 (0.41) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL1204596 | 0.85 | CTSS (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL20028616 | 0.85 | CTSS (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL12189209 | 0.85 | CTSS (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL1204594 | 0.85 | CTSS (0.54) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL14778518 | 0.85 | CTSK (0.53) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL3212854 | 0.85 | CTSK (0.53) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL3212857 | 0.85 | CTSK (0.53) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2024-09-12 | — | — | US | disclosed |
| EP-4352049-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Avelos Therapeutics Inc. (KR) | 2024-04-17 | — | — | EP | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
| US-11505551-B2 | Methods for preparing substituted pyridinone-containing tricyclic compounds | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-11-22 | — | — | US | disclosed |
| US-20210032246-A1 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-02-04 | — | — | US | disclosed |
| US-20210032246-A1 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-02-04 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| EP-1539727-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CELLULAR PROLIFERATIVE DISEASES | CYTOKINETICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491746-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20060247287-A1 | Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | ONO PHARMACEUTICAL CO., LTD. | 2003-08-14 | — | — | US | disclosed |
| US-6534658-B1 | Intermediates for producing pharmaceuticals | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-1162199-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-5773468-A | Irreversible HIV protease inhibitor having an anti-aids activity and process for the preparation thereof | LG CHEMICAL LIMITED (KR) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | CTSK 1326/4885CTSS 1434/4885CA2 2768/4885 |
| US-11505551-B2 | Methods for preparing substituted pyridinone-containing tricyclic compounds | HMBS, TYMP, HAVCR2 | CTSK 1116/4885CTSS 804/4885CA2 4869/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | CTSK 1326/4885CTSS 1434/4885CA2 2768/4885 |
| US-20210032246-A1 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS | HMBS, TYMP, HAVCR2 | CTSK 1116/4885CTSS 804/4885CA2 4869/4885 |
| US-20060247287-A1 | Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses | HAVCR2, HCCS, AADAC | CTSK 1050/4885CTSS 532/4885CA2 4160/4885 |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | MAST1, MAST3, MAST4 | CTSK 580/4885CTSS 1147/4885CA2 2424/4885 |
| US-20030153758-A1 | 1,3,4-Oxadiazole derivatives and process for producing the same | OXA1L, CYP1B1, OXER1 | CTSK 3506/4885CTSS 4452/4885CA2 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.